To NASDAQ OMX Copenhagen A/S
Investor News No. 04-12 / Copenhagen, August 23, 2012
Copenhagen, Denmark – August 23, 2012 – Topotarget A/S (NASDAQ OMX: TOPO) announces that a teleconference will be held on August 29, 2012 at 1:00 pm CET. CEO Francois Martelet, CMDO Axel Mescheder, and CFO Anders Vadsholt will present the interim report for Q2 2012 and answer questions. The teleconference will be conducted in English. A presentation will be available on Topotarget’s website, www.topotarget.com, before the start of the conference call.
To participate in the conference call please dial:
- From Denmark: 32 72 76 25
- Outside Denmark: +44 (0) 1452 555566
A replay of the conference call will be available approximately four hours after the conference call and until September 11, 2012 at: +45 70 14 21 68 or +44 (0) 145 255 0000, pass code: #22283673. A replay will also be available on Topotarget's website www.topotarget.com.
Topotarget A/S
For further information, please contact:
Anders Vadsholt, CFO: Direct: +45 39 17 83 45
Background information
About Topotarget A/S
Topotarget (NASDAQ-OMX: TOPO) is an international biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. Topotarget focuses, in collaboration with Spectrum Pharmaceuticals, Inc., on the development in pivotal studies of its lead drug candidate, belinostat, which has shown positive results as a monotherapy treating hematological malignancies and positive results in solid tumors. Belinostat may be used in combination with full doses of chemotherapy, and is in a pivotal trial within PTCL (peripheral T-cell lymphoma). For more information, please visit www.topotarget.com.
Topotarget A/S Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about our expectations of the progression of our pre-clinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Topotarget A/S cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of Topotarget A/S will not proceed as planned for technical, scientific, or commercial reasons or due to patient enrollment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; Topotarget A/S' history of incurring losses and the uncertainty of achieving profitability; Topotarget A/S' stage of development as a biopharmaceutical company; government regulation; patent infringement claims against Topotarget A/S' products, processes, and technologies; the ability to protect Topotarget A/S' patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.